Pharming Group N.V.

ENXTAM:PHARM Rapporto sulle azioni

Cap. di mercato: €513.9m

Pharming Group Gestione

Gestione criteri di controllo 2/4

Pharming Group Il CEO è Simon de Vries, nominato in Nov2008, e ha un mandato di 16.08 anni. la retribuzione annua totale è $ 2.81M, composta da 24% di stipendio e 76% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.13% delle azioni della società, per un valore di € 10.96M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 3.7 anni.

Informazioni chiave

Simon de Vries

Amministratore delegato

US$2.8m

Compenso totale

Percentuale dello stipendio del CEO24.0%
Mandato del CEO16yrs
Proprietà del CEO2.1%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03
Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12
Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Simon de Vries rispetto agli utili di Pharming Group?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$3mUS$673k

-US$11m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$636k

US$14m

Sep 30 2022n/an/a

US$30m

Jun 30 2022n/an/a

US$21m

Mar 31 2022n/an/a

US$11m

Dec 31 2021US$3mUS$681k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$31m

Mar 31 2021n/an/a

US$37m

Dec 31 2020US$3mUS$614k

US$38m

Sep 30 2020n/an/a

US$44m

Jun 30 2020n/an/a

US$46m

Mar 31 2020n/an/a

US$42m

Jan 01 2020n/an/a

US$41m

Sep 30 2019n/an/a

US$38m

Jun 30 2019n/an/a

US$34m

Mar 31 2019n/an/a

US$29m

Dec 31 2018US$2mUS$579k

US$29m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$80m

Dec 31 2017US$2mUS$537k

-US$91m

Compensazione vs Mercato: La retribuzione totale di Simon ($USD 2.81M ) è superiore alla media delle aziende di dimensioni simili nel mercato Dutch ($USD 874.94K ).

Compensazione vs guadagni: La retribuzione di Simon è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Simon de Vries (65 yo)

16yrs

Mandato

US$2,809,000

Compensazione

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Sijmen de Vries
President16yrsUS$2.81m2.13%
€ 11.0m
Jeroen Wakkerman
Chief Financial Officer4yrsNessun dato0.064%
€ 326.3k
Mireille Sanders
Chief Operations Officer5.3yrsNessun dato0.12%
€ 605.3k
Susanne Embleton
Investor Relations Managerno dataNessun datoNessun dato
Ruud Van Outersterp
Chief Ethics & Compliance Officer3.5yrsNessun dato0.024%
€ 125.1k
Anurag Relan
Chief Medical Officer3.4yrsNessun dato0.027%
€ 139.6k
Stephen Toor
Chief Commercial Officer & GM Americas7.8yrsNessun dato0.028%
€ 142.2k
Alexander Breidenbach
Chief Business Officer1.2yrsNessun dato0.0096%
€ 49.5k
Bruno M. Giannetti
Consultant3.4yrsNessun datoNessun dato

3.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di PHARM è considerato esperto (durata media dell'incarico 3.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Sijmen de Vries
President16.1yrsUS$2.81m2.13%
€ 11.0m
Leonard Kruimer
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 91.8k
Mark Pykett
Independent Non-Executive Director3.9yrsUS$87.00k0.022%
€ 110.6k
Deborah Jorn
Independent Non-Executive Vice-Chairperson5.5yrsUS$87.00k0.024%
€ 122.5k
Steven Baert
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 91.8k
Barbara Yanni
Independent Non-Executive Director3.9yrsUS$94.00k0.022%
€ 110.6k
Richard Peters
Non-Executive Chairman of Board1.2yrsUS$46.00k0.0093%
€ 47.6k
Jabine van der Meijs
Independent Non-Executive Director3.5yrsUS$94.00k0.018%
€ 91.8k

3.7yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHARM sono considerati esperti (durata media dell'incarico 3.7 anni).